Vepugratinib

Phase 2Small molecule

Eli Lilly

Vepugratinib is one of 10 small molecule programs targeting Urinary Bladder Neoplasms. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary Bladder NeoplasmsNot yet recruiting

Urinary Bladder NeoplasmsPhase 2

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Urinary Bladder Neoplasms

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

3 2

Lynparza

AstraZeneca

Phase 2

1 3

Padcev

Pfizer

Phase 1

2 4

Keytruda

Merck & Co.

Phase 1

1 5

Crestor

AstraZeneca

Phase 1

1 6

Versed

CConrado Roberto Hoffmann Filho

Phase 1

1 7

Lanoxin

AAdvanz Pharma

Phase 1

1 8

Trastuzumab Deruxtecan

AstraZeneca

Phase 1

1 9

Tuoyi

SSun Yat-sen University

Preclinical

1 10

Vepugratinib

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Urinary Bladder Neoplasms

NCT05614739

Q1 2031

Phase 2Not yet recruiting

Urinary Bladder Neoplasms

NCT07827612

Q2 2033

Phase 3Recruiting

Carcinoma, Transitional Cell

NCT07218380

Clinical

Trials by Indication[1]

Urinary Bladder Neoplasms3 trials

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT05614739·677 enrolled

FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

Not yet recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07827612·161 enrolled

Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Available· Eli Lilly logo

Eli Lilly··NCT07675057

Carcinoma, Transitional Cell1 trial

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07218380·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Vepugratinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vepugratinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vepugratinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

Vepugratinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2031

Q2 2033

Trials by Indication[1]

Urinary Bladder Neoplasms3 trials

Carcinoma, Transitional Cell1 trial

References

Drug Info

Quick Facts

Related News